Company

Mission

The mission of Radetec Diagnostics is to contribute to the fight against Sexually Transmitted Infections and other infectious diseases such as COVID-19, improving the well-being of the society and helping in the elimination of prejudices and taboos. Radetec Diagnostics focuses on the global challenges of our time, aiming to achieve global impact with its ground-breaking rapid test technology and remove the barriers that get in the way of securing your health. Radetec Diagnostics is closely working with highly experienced partners, material suppliers and contract manufacturers around the world, to offer outstanding products and services, making difficult applications possible.

 

Technology

Radetec Diagnostics developed a new way to produce highly-fluorescent quantum dots stable in buffers, which can be linked to several biologically-active molecules (e.g. antibodies). These quantum dots have successfully employed in our rapid tests for Sexually Transmitted Infections and COVID-19. Visit our quantum dots page for more information about our technology.

    

R&D services

Radetec Diagnostic commercialise reagents and equipment for lateral flow assay development through its website LateralFlows.com. Our quantum dots technology can be licensed to third parties, to be integrated in their products.

 

Timeline

  • Q1 2020. Radetec Diagnostics started developing its COVID-19 test.
  • Q4 2019. Pre-clinical study of Radetec’s Chlamydia test.
  • Q3 2019. Recipient of a Small Business grant from the City of Melbourne. Completed a Freedom To Operate search.
  • Q2 2019. Seed funding raised from Alternative Investments. Started a research partnership with the University of Technology Sydney and Griffith University.
  • Q1 2019. Radetec Diagnostics was selected to be part of the The Actuator – Australia’s national medtech accelerator.
  • Q4 2018. First sale of Radetec’s quantum dots. Several prizes and competitions won internationally. Finalist of the MedTech’s Got Talent challenge.
  • Q1-Q3 2018. Optimisation of the QDs-based lateral flow test.
  • Q4 2017. First successful test of a human virus in blood serum.
  • Q3 2017. Development of the biomembrane for conjugation of proteins with QDs complete.
  • June 2016. Radetec Diagnostics was formed in Melbourne, Australia